Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for oral use. It treats severe plaque psoriasis, pustular psoriasis and ichthyosis in adult patients.

GNH USA supplies Neotigason as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason is a systemic retinoid used in dermatologic disorders that involve abnormal keratinocyte proliferation. - Severe plaque psoriasis: reduces scaling, plaque thickness and erythema. - Pustular psoriasis: helps control pustule formation and skin inflammation. - Ichthyosis: normalizes keratinocyte differentiation to improve the skin barrier.

Acitretin may cause a range of adverse reactions, which are commonly categorized by frequency.

Common Side Effects: - Dry skin: increased scaling and itching. - Cheilitis: inflammation and cracking of the lips. - Elevated triglycerides: rise in blood lipid levels. - Hair loss: temporary alopecia.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevation or injury. - Severe hyperlipidemia: marked increase in cholesterol or triglycerides. - Pseudotumor cerebri: increased intracranial pressure. - Bone toxicity: premature epiphyseal closure in children.

Before initiating therapy, clinicians should assess several safety parameters. - Pregnancy: contraindicated due to high teratogenic risk (Category X). - Women of childbearing potential: must use effective contraception during treatment and for at least three years after discontinuation. - Liver function: monitor hepatic enzymes before and during therapy. - Lipid profile: assess serum triglycerides and cholesterol regularly. - Bone health: avoid use in children and monitor for skeletal effects. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and light.

Acitretin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive toxicity. - Systemic corticosteroids: may reduce acitretin efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - Phenytoin: may lower acitretin plasma levels. - Oral contraceptives: reduced effectiveness, requiring additional barrier methods.